Business
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
Seven oral and poster presentations highlighted during meeting Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and presented during the
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nSeven oral and poster presentations highlighted during meeting\n\n\n\n\nPhase 3 MARCH PFIC data selected as one of highest scoring abstracts and presented during the plenary session\n\n\n\n\nRISE study evaluating LIVMARLI in infants with ALGS and PFIC included among highest scoring posters\n\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting. Among the data presented were four oral and three poster presentations featuring analyses from LIVMARLI® (maralixibat) oral solution clinical studies.\n\n\n“We are thrilled to present data further underscoring LIVMARLI’s potential to help patients with ALGS and PFIC, two debilitating cholestatic diseases affecting children,” said Pam Vig, PhD, head of research and development at Mirum. “Further analyses from the MARCH-PFIC study continue to highlight LIVMARLI’s potential to benefit patients across a broad range of PFIC types. In ALGS, the data continue to support LIVMARLI’s safety and efficacy profile, including in infants under 12 months of age as well as in the real-world setting. We are proud to present data across multiple parameters, including improvements in pruritus, serum bile acids, and also in xanthomas which can be painful, disfiguring and debilitating for many patients.”\n\n\nA summary of data from the oral presentations at ESPGHAN, featuring LIVMARLI, are enclosed:\n\n\nAbstract 477 – H-O027: Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH-PFIC): A randomized placebo-controlled Phase 3 study\nThursday, May 18, 2023 - 11:45am-1:15pm CET - Plenary Session, Highest Scoring Abstracts, Hall A\nPresented at 1:02pm CET by Professor Richard J. Thompson, King’s College, London\n\n\nThe MARCH-PFIC study is the largest Phase 3 trial conducted in children with PFIC including PFIC types that had not been previously studied. The data showed that the primary and secondary endpoints were met with LIVMARLI demonstrating significant and rapid improvements in pruritus and serum bile acids (sBAs) across all PFIC types. Data from the All-PFIC cohort showed significant improvements in bilirubin and weight z-scores as well as a trend in height z-score improv...